Oxaliplatin-related neurotoxicity: how and why?

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Critical reviews in oncology/hematology

• Publication date

  2006-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.CRITREVONC.2006.01.001PMID 16806962
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Survival results of NSABP Protocol C-07

  2005cited by this paper
• Oxaliplatin-Associated Neuropathy: A Review

  2005cited by this paper
• A phase II study of oxaliplatin, capecitabine and bevacizumab in the treatment of metastatic colorectal cancer

  2005cited by this paper
• High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer.

  2005cited by this paper
• Oxaliplatin‐induced neurotoxicity and the development of neuropathy

  2005cited by this paper
• Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: Efficacy results with a median follow-up of 4 years

  2005cited by this paper
• High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200

  2005cited by this paper
• Clinical management of oxaliplatin-associated neurotoxicity.

  2005cited by this paper
• A phase III double blinded, placebo controlled, randomized trial of gabapentin in patients with chemotherapy-induced peripheral neuropathy: A North Central Cancer Treatment Group study

  2005cited by this paper
• Oxaliplatin‐induced neurotoxicity: Acute hyperexcitability and chronic neuropathy

  2004cited by this paper
• Prevention of Oxaliplatin-Related Neurotoxicity by Calcium and Magnesium Infusions

  2004cited by this paper
• XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.

  2004cited by this paper
• Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.

  2004cited by this paper
• FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.

  2004cited by this paper
• Genomic profiling as predictor of toxicity in patients with advanced colorectal cancer treated with platinum-based chemotherapy.

  2004cited by this paper
• Dysphonia as an Unusual Toxic Event of Oxaliplatin-Based Chemotherapy

  2004cited by this paper
• A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

  2004cited by this paper
• Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

  2004cited by this paper
• Phase II study of CC-4047 in patients with metastatic hormone-refractory prostate cancer (HRPCa).

  2004cited by this paper
• Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.

  2003cited by this paper
• Ongoing prospective multicenter safety study of the cytoprotectant amifostine given subcutaneously: overview of trial design.

  2003cited by this paper
• Therapeutic strategies for metastatic colorectal cancer: simultaneous, sequential, or specific?

  2003cited by this paper
• Oxaliplatin-safety profile: neurotoxicity.

  2003cited by this paper
• Acute oxaliplatin-induced peripheral nerve hyperexcitability.

  2002cited by this paper
• Exacerbation of oxaliplatin neurosensory toxicity following surgery.

  2002cited by this paper
• Circulating nerve growth factor level changes during oxaliplatin treatment-induced neurotoxicity in the rat.

  2002cited by this paper
• Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid.

  2002cited by this paper
• Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial.

  2002cited by this paper
• Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures.

  2002cited by this paper
• Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer.

  2002cited by this paper
• Failure to find evidence for association between voltage-gated sodium channel gene SCN2A variants and febrile seizures in humans.

  2002cited by this paper
• [Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study].

  2002cited by this paper
• Subcutaneous administration of amifostine: a promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy.

  2001cited by this paper
• Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat.

  2001cited by this paper
• An overview of chemotherapy-induced peripheral sensory neuropathy, focusing on oxaliplatin.

  2001cited by this paper
• A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels.

  2001cited by this paper
• A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer.

  2001cited by this paper
• High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7).

  2001cited by this paper
• Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

  2000cited by this paper
• The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons.

  2000cited by this paper
• Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs

  2000cited by this paper
• Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR.

  1999cited by this paper
• Pharmacokinetics and safety profile of oxaliplatin.

  1998cited by this paper
• Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model.

  1998cited by this paper
• Oxaliplatin: a review of preclinical and clinical studies.

  1998cited by this paper
• Glutathione-related mechanisms in cellular resistance to anticancer drugs.

  1998cited by this paper
• A phase II and pharmacokinetic study of enloplatin in patients with platinum refractory advanced ovarian carcinoma

  1997cited by this paper
• Zeniplatin in advanced malignant melanoma and renal cancer: phase II studies with unexpected nephrotoxicity

  1997cited by this paper
• Pharmacokinetics of elemental platinum (ultrafiltrate and total) after a thirty minute intravenous infusion of ormaplatin.

  1997cited by this paper
• Transfection of glutathione S-transferase (GST)-pi antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, melphalan, and etoposide.

  1996cited by this paper
• A phase II study of CI-973 [SP-4-3(R)]- [1, 1-cyclobutane-dicarboxylato (2-)] (2-methyl-1,4-butanediamine-N, N′) platinum in patients with refractory advanced breast cancer

  1996cited by this paper

• Concomitant Use of DPP‐4 Inhibitors May Prevent the Development of Oxaliplatin‐Induced Peripheral Neuropathy: A Retrospective Cohort Study

  2026cites this paper
• Lycium Barbarum Polysaccharide‐based Hydrogel as a Novel Oral Colon‐Targeted Drug Delivery System for Enhanced MSS‐CRC Treatment by Macrophage Lipid Reprogramming

  2026cites this paper
• Targeting the FGF1/FGFR signaling pathway enhances the antitumor effect of oxaliplatin and alleviates chemotherapy-induced peripheral neuropathy.

  2026cites this paper
• Proton pump inhibitor concomitant use to prevent oxaliplatin‐induced peripheral neuropathy: Clinical retrospective cohort study

  2025cites this paper
• Central vs. Peripheral Venous Oxaliplatin Administration and Chemotherapy-Induced Peripheral Neuropathy Severity.

  2025cites this paper
• Antihyperalgesic Activity of Propoxazepam in the Oxaliplatin-Induced Cold Allodynia in Rats

  2025influential citation
• Oxaliplatin-loaded natural killer cell-derived exosomes for a safe and efficient chemoimmunotherapy of colorectal cancer.

  2025cites this paper
• Increased TRPA1 functionality in the skin of rats and cancer patients following oxaliplatin treatment.

  2025cites this paper
• An optical/magnetic imaging nanoplatform-mediated convection-enhanced delivery of oxaliplatin for glioma treatment.

  2025cites this paper
• Carboplatin-induced reversible ptosis

  2024cites this paper
• Total glucosides of paeony ameliorates chemotherapy-induced neuropathic pain by suppressing microglia pyroptosis through the inhibition of KAT2A-mediated p38 pathway activation and succinylation

  2024cites this paper
• Sex differences in recovery from postoperative sarcopenia during adjuvant CAPOX therapy for colorectal cancer

  2024cites this paper
• Recent advances in cancer therapy‐associated oral mucositis

  2024cites this paper
• The Association between Oxaliplatin-Induced Peripheral Neuropathy, Sociodemographic, and Clinical Characteristics with Falls in Older Adults with Colorectal Cancer.

  2024cites this paper
• Biological Mediators and Partial Regulatory Mechanisms on Neuropathic Pain Associated With Chemotherapeutic Agents.

  2024cites this paper
• Neuroprotective Effect of Polyvalent Immunoglobulins on Mouse Models of Chemotherapy-Induced Peripheral Neuropathy

  2024cites this paper
• Near-Infrared Visualization of NAD(P)H Dynamics in Live Cells and Drosophila melanogaster Larvae Using a Coumarin-Based Pyridinium Fluorescent Probe.

  2024cites this paper
• Will the Interactions of Some Platinum (II)-Based Drugs with B-Vitamins Reduce Their Therapeutic Effect in Cancer Patients? Comparison of Chemotherapeutic Agents such as Cisplatin, Carboplatin and Oxaliplatin—A Review

  2023cites this paper
• Platinum drugs-related safety profile: The latest five-year analysis from FDA adverse event reporting system data

  2023cites this paper
• Linarin attenuates oxaliplatin-induced neuropathic pain by inhibiting NF-κB/NLRP3 signaling pathway

  2023cites this paper
• Development and validation of the chemotherapy-induced peripheral neuropathy integrated assessment – oxaliplatin subscale: a prospective cohort study

  2023cites this paper
• Cardiovascular Diseases in Oncological Patients Treated at a Tertiary Hospital in the Northern Macroregion of Rio Grande do Sul

  2023influential citation
• Falls during oxaliplatin-based chemotherapy for gastrointestinal malignancies – (lessons learned from) a prospective study

  2023cites this paper
• Role of inflammation and oxidative stress in chemotherapy-induced neurotoxicity

  2022cites this paper
• Advances in Chemoradiotherapy for Treatment of Colon Cancer

  2022cites this paper
• [6]-Shogaol Attenuates Oxaliplatin-Induced Allodynia through Serotonergic Receptors and GABA in the Spinal Cord in Mice

  2022cites this paper
• Wnt3a/YTHDF1 Regulated Oxaliplatin-Induced Neuropathic Pain Via TNF-α/IL-18 Expression in the Spinal Cord

  2022cites this paper
• Identification of prophylactic drugs for oxaliplatin-induced peripheral neuropathy using big data.

  2022cites this paper
• Oxaliplatin delivery via chitosan/vitamin E conjugate micelles for improved efficacy and MDR-reversal in breast cancer.

  2022cites this paper
• Antioxidant and Neuroprotective Effect of a Grape Pomace Extract on Oxaliplatin-Induced Peripheral Neuropathy in Rats: Biochemical, Behavioral and Histopathological Evaluation

  2022cites this paper
• Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Patients Receiving 4–6 Cycles of Platinum-Based and Taxane-Based Chemotherapy: A Prospective, Single-Center Study from Kosovo

  2022cites this paper
• Omeprazole Suppresses Oxaliplatin-Induced Peripheral Neuropathy in a Rodent Model and Clinical Database

  2022cites this paper
• Distortion Product Otoacoustic Emission Test is Not the Test to Use in Nonclinical Safety Assessment

  2022cites this paper
• Ramipril Alleviates Oxaliplatin-Induced Acute Pain Syndrome in Mice

  2021cites this paper
• Nanoparticle-based drug delivery systems with platinum drugs for overcoming cancer drug resistance.

  2021cites this paper
• Multifunctional injectable hydrogels for three-in-one cancer therapy: Preoperative remission via mild photothermal-enhanced supramolecular chemotherapy and prevention of postoperative recurrence and adhesion

  2021cites this paper
• Liposomalization of oxaliplatin exacerbates the non-liposomal formulation-induced decrease of sweet taste sensitivity in rats.

  2021cites this paper
• Therapeutic Agents for Oxaliplatin-Induced Peripheral Neuropathy; Experimental and Clinical Evidence

  2021cites this paper
• Nanoparticle-mediated convection-enhanced delivery of a DNA intercalator to gliomas circumvents temozolomide resistance

  2021cites this paper
• Roles of RAD18 in DNA replication and post-replication repair (PRR)

  2021cites this paper
• Mitosis Inhibitors and Medicinal Plants: Neurotoxicity and Neuroprotection

  2021cites this paper
• Epigenetics Involvement in Oxaliplatin-Induced Potassium Channel Transcriptional Downregulation and Hypersensitivity

  2021cites this paper
• Seaweeds: Potential Candidates in Human Colon Cancer Therapy

  2021cites this paper
• Neurotoxicity of antineoplastic drugs: Mechanisms, susceptibility, and neuroprotective strategies.

  2020cites this paper
• Ototoxicity and Platinum Uptake Following Cyclic Administration of Platinum-Based Chemotherapeutic Agents

  2020cites this paper
• Protective effect of the oral administration of cystine and theanine on oxaliplatin-induced peripheral neuropathy: a pilot randomized trial

  2020cites this paper
• Neuroprotective effect of alogliptin on oxaliplatin-induced peripheral neuropathy in vivo and in vitro

  2020cites this paper
• A phase I study of docetaxel/oxaliplatin/S-1 (DOS) combination neoadjuvant chemotherapy for patients with locally advanced adenocarcinoma of the esophagogastric junction

  2020cites this paper
• Postoperative Exacerbation of Oxaliplatin-induced Neurotoxicity in Gastrointestinal Cancers: A Case Series

  2020cites this paper
• Oral administration of Cystine and Theanine ameliorates oxaliplatin-induced chronic peripheral neuropathy in rodents

  2020cites this paper
• Inhibition of microRNA-155 Reduces Neuropathic Pain During Chemotherapeutic Bortezomib via Engagement of Neuroinflammation

  2020cites this paper
• Efficacy of the World Health Organization analgesic ladder in the paclitaxel-induced pain syndrome in rats

  2020cites this paper
• Imbalanced Subthreshold Currents Following Sepsis and Chemotherapy: A Shared Mechanism Offering a New Therapeutic Target?

  2020cites this paper
• DNA polymerase eta: A potential pharmacological target for cancer therapy

  2020cites this paper
• Efficacy of the World Health Organization analgesic ladder in the paclitaxel-induced pain syndrome in rats

  2020cites this paper
• The Role of Satellite Glial Cells, Astrocytes, and Microglia in Oxaliplatin-Induced Neuropathic Pain

  2020cites this paper
• Treatment of Chronic Oxaliplatin-Induced Peripheral Neuropathy: A Systematic Review

  2020cites this paper
• Danggui Sini decoction protects against oxaliplatin-induced peripheral neuropathy in rats.

  2020cites this paper
• Neuroprotective Effects of an Aqueous Extract of Forsythia viridissima and Its Major Constituents on Oxaliplatin-Induced Peripheral Neuropathy

  2019cites this paper
• Dimethyl Fumarate Attenuates Oxaliplatin-Induced Peripheral Neuropathy without Affecting the Anti-tumor Activity of Oxaliplatin in Rodents.

  2019cites this paper
• Electroacupuncture enhances antioxidative signal pathway and attenuates neuropathic pain induced by chemotherapeutic paclitaxel.

  2019cites this paper
• Transcription factor Sp4 is required for hyperalgesic state persistence

  2019cites this paper
• Polyneuropathie bei Patienten mit onkologischen Erkrankungen

  2019cites this paper
• Ameliorative effects of aqueous extract of Forsythiae suspensa fruits on oxaliplatin-induced neurotoxicity in vitro and in vivo

  2019cites this paper
• Skin platinum deposition in colorectal cancer patients following oxaliplatin-based therapy

  2019cites this paper
• Donepezil ameliorates oxaliplatin-induced peripheral neuropathy via a neuroprotective effect.

  2019cites this paper
• Assessment of Oxaliplatin-induced Chronic Neuropathy and Anticancer Efficacy Through Pharmacokinetic and Toxicodynamic Evaluation of a Rat Model of Colorectal Cancer

  2019cites this paper
• Medical Oncologists' Perspectives on How the Results of the IDEA Collaboration Impact the Adjuvant Treatment of Stage III Colon Cancer.

  2019cites this paper
• Electrophysiologic evaluation of facial nerve functions after oxaliplatin treatment

  2019cites this paper
• Engagement of MicroRNA-155 in Exaggerated Oxidative Stress Signal and TRPA1 in the Dorsal Horn of the Spinal Cord and Neuropathic Pain During Chemotherapeutic Oxaliplatin

  2019influential citation
• Dysphagia in solid malignancies outside the head, neck and upper gastrointestinal tract

  2019cites this paper
• Long‐term effects after treatment with platinum compounds, cisplatin and [Pt(O,O′‐acac)(&ggr;‐acac)(DMS)]: Autophagy activation in rat B50 neuroblastoma cells

  2019cites this paper
• Use of anticancer platinum compounds in combination therapies and challenges in drug delivery.

  2018cites this paper
• Systematic evaluation of clinical and experimental evidence for the application of Chinese herbal medicines in the management of colorectal cancer

  2018cites this paper
• Chemotherapy-Induced Peripheral Neuropathy in Egyptian Patients: Single Institution Retrospective Analysis

  2018cites this paper
• Identification of drug transporters contributing to oxaliplatin‐induced peripheral neuropathy

  2018cites this paper
• Optical examination of the efficacy of contact needle therapy for chemotherapy-induced peripheral neuropathy: integration of inspection in Kampo therapy with color spectrum information

  2018cites this paper
• Light It Up: A Pre-Clinical Fluorescent Model to Illustrate Immunogenic Cell Death

  2018cites this paper
• Rosmarinic Acid Mitigates Mitochondrial Dysfunction and Spinal Glial Activation in Oxaliplatin-induced Peripheral Neuropathy

  2018cites this paper
• Participation of pro-inflammatory cytokines in neuropathic pain evoked by chemotherapeutic oxaliplatin via central GABAergic pathway

  2018cites this paper
• Involvement of pro-inflammation signal pathway in inhibitory effects of rapamycin on oxaliplatin-induced neuropathic pain

  2018cites this paper
• Changes in upper extremity function, ADL, and HRQoL in colorectal cancer patients after the first chemotherapy cycle with oxaliplatin: a prospective single-center observational study

  2018cites this paper
• Analysis of reduced-dose administration of oxaliplatin as adjuvant FOLFOX chemotherapy for colorectal cancer

  2018cites this paper
• Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity.

  2018cites this paper
• Rapamycin alleviates proinflammatory cytokines and nociceptive behavior induced by chemotherapeutic paclitaxel

  2018cites this paper
• Nociceptive behavior induced by chemotherapeutic paclitaxel and beneficial role of antioxidative pathways.

  2018cites this paper
• Chinese Herbal Medicines Facilitate the Control of Chemotherapy-Induced Side Effects in Colorectal Cancer: Progress and Perspective

  2018cites this paper
• STUDY OF THE MECHANISM OF ACTION FOR Ru(II) POLYPYRIDYL COMPLEXES AS POTENTIAL ANTICANCER AGENTS

  2018cites this paper
• Blocking TRPA1 and TNF-α Signal Improves Bortezomib-Induced Neuropathic Pain

  2018cites this paper
• Factor-κB-dependent Histone Acetylation Is Involved in Paclitaxel-induced Peripheral Neuropathy

  2017cites this paper
• Ion channels and neuronal hyperexcitability in chemotherapy-induced peripheral neuropathy

  2017cites this paper
• Mechanisms of the analgesic effect of calcitonin on chronic pain by alteration of receptor or channel expression

  2017cites this paper
• Brain activity changes in a macaque model of oxaliplatin-induced neuropathic cold hypersensitivity

  2017cites this paper
• Anti-allodynic effect of Buja in a rat model of oxaliplatin-induced peripheral neuropathy via spinal astrocytes and pro-inflammatory cytokines suppression

  2017cites this paper
• Platinum-induced neurotoxicity: A review of possible mechanisms

  2017cites this paper
• Melatonin prevents mitochondrial dysfunction and promotes neuroprotection by inducing autophagy during oxaliplatin‐evoked peripheral neuropathy

  2017cites this paper
• The molecular genetics of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis.

  2017cites this paper
• A pH responsive complexation-based drug delivery system for oxaliplatin

  2017cites this paper
• Douleurs aiguës et chroniques induites par les traitements médicamenteux du cancer

  2017cites this paper
• Investigation on effect of basalin coated silver nanoparticles as antioxidant for alleviating peripheral neuropathy in mice treated with oxaliplatin.

  2017cites this paper